九安医疗(002432) - 2023 Q3 - 季度财报

Financial Performance - Revenue for Q3 2023 was ¥462,297,847.35, a decrease of 65.05% compared to the same period last year, and a total revenue of ¥2,745,050,759.03 for the year-to-date, down 88.84% year-on-year [3]. - Net profit attributable to shareholders for Q3 2023 was ¥110,916,359.76, down 86.25% year-on-year, with a year-to-date net profit of ¥896,732,603.94, a decrease of 94.41% [3]. - Basic earnings per share for Q3 2023 was ¥0.2356, a decline of 86.68%, while diluted earnings per share was ¥0.2310, down 86.55% [3]. - Total operating revenue for the current period is ¥2,745,050,759.03, a significant decrease from ¥24,589,378,264.71 in the previous period, representing a decline of approximately 88.83% [16]. - Total operating costs for the current period are ¥1,662,027,861.60, down from ¥5,977,811,319.07 in the previous period, indicating a reduction of about 72.14% [16]. - Net profit for the current period is ¥983,181,037.09, compared to ¥17,190,203,671.36 in the previous period, reflecting a decrease of approximately 94.27% [17]. - Total comprehensive income for the current period is ¥1,558,442,311.48, compared to ¥18,414,090,024.48 in the previous period, reflecting a decline of about 91.52% [18]. Assets and Liabilities - Total assets at the end of Q3 2023 were ¥22,246,455,354.91, an increase of 2.37% from the end of the previous year [3]. - Total current assets decreased from RMB 13.19 billion on January 1, 2023, to RMB 9.83 billion as of September 30, 2023, a decline of approximately 25.5% [14]. - Total non-current assets increased from RMB 8.54 billion on January 1, 2023, to RMB 12.42 billion as of September 30, 2023, an increase of approximately 45.5% [14]. - The company’s total liabilities increased from RMB 1.71 billion on January 1, 2023, to RMB 2.26 billion as of September 30, 2023, an increase of approximately 32.3% [15]. - The company’s equity attributable to shareholders decreased from RMB 19.55 billion on January 1, 2023, to RMB 19.42 billion as of September 30, 2023, a decline of approximately 0.7% [15]. Cash Flow - Cash flow from operating activities for the year-to-date was ¥1,752,388,418.26, down 90.10% compared to the same period last year [3]. - The company reported a net cash inflow from operating activities of ¥3,159,199,950.53, down from ¥24,955,452,068.62 in the previous period, indicating a decrease of about 87.37% [19]. - Cash received from sales of goods and services dropped by 88.39% to CNY 2,842,437,755.32, mainly due to a decline in sales of test kits [8]. - The net cash flow from investment activities was -4,923,713,764.53 CNY, compared to -7,995,469,955.09 CNY in the previous year [20]. - Total cash inflow from financing activities was 995,418,132.15 CNY, significantly higher than 200,441,553.43 CNY in the same period last year [20]. - The cash and cash equivalents at the end of the period amounted to 1,452,131,961.78 CNY, down from 10,285,626,265.87 CNY at the end of the previous year [20]. Investments and Expenses - The company reported a significant increase in investment income, which rose to ¥296,758,122.96 from ¥9,253,392.74 in the previous period, marking a growth of approximately 3,109.73% [17]. - Research and development expenses increased to ¥208,123,925.62 from ¥165,854,982.39 in the previous period, showing an increase of approximately 25.49% [16]. - Cash paid for investment increased by 40.46% to CNY 12,636,430,764.51, reflecting higher investments in financial assets [8]. - The company experienced an 85.54% decrease in income tax expenses, amounting to CNY 180,397,471.89, due to reduced operating profit from declining test kit sales [8]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 115,715 [9]. - As of September 30, 2023, the total amount spent on share repurchases reached approximately RMB 612.8 million, with 16,609,140 shares repurchased [12]. - By October 16, 2023, the total amount spent on share repurchases increased to approximately RMB 749.4 million, with 20,300,704 shares repurchased [12]. - The company distributed dividends totaling CNY 1,181,773,371.01, an increase of 267.55% compared to the previous period [8]. Miscellaneous - The company reported a significant decrease in inventory, down 61.21% to ¥270,599,912.44, primarily due to reduced production and inventory impairment [7]. - Short-term borrowings increased by 230.77% to ¥860,000,000.00, reflecting a rise in bank loans during the reporting period [7]. - The company did not undergo an audit for the third quarter report [21].